Since 1999, when Ralph weissleder from Harvard University first reported the noninvasive imaging technology–Molecular Imaging, it is a useful tool that can measure and characterize a variety of biological processes at the cellular or molecular levels in vivo [11], and which could therefore be utilized to identify EGFR activating mutations and to assess tumor response to EGFR-TKIs therapy in vivo. The gene discussed is EGFR; the disease is neoplasm.